These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 34868036)

  • 1. Immunogenicity and Protective Potential of Mucosal Vaccine Formulations Based on Conserved Epitopes of Influenza A Viruses Fused to an Innovative Ring Nanoplatform in Mice and Chickens.
    Calzas C; Mao M; Turpaud M; Viboud Q; Mettier J; Figueroa T; Bessière P; Mangin A; Sedano L; Hervé PL; Volmer R; Ducatez MF; Bourgault S; Archambault D; Le Goffic R; Chevalier C
    Front Immunol; 2021; 12():772550. PubMed ID: 34868036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel subnucleocapsid nanoplatform for mucosal vaccination against influenza virus that targets the ectodomain of matrix protein 2.
    Hervé PL; Raliou M; Bourdieu C; Dubuquoy C; Petit-Camurdan A; Bertho N; Eléouët JF; Chevalier C; Riffault S
    J Virol; 2014 Jan; 88(1):325-38. PubMed ID: 24155388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross protection by inactivated recombinant influenza viruses containing chimeric hemagglutinin conjugates with a conserved neuraminidase or M2 ectodomain epitope.
    Kim KH; Jung YJ; Lee Y; Park BR; Oh J; Lee YN; Kim MC; Jeeva S; Kang SM
    Virology; 2020 Nov; 550():51-60. PubMed ID: 32882637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant baculovirus vaccine containing multiple M2e and adjuvant LTB induces T cell dependent, cross-clade protection against H5N1 influenza virus in mice.
    Zhang J; Fan HY; Zhang Z; Zhang J; Zhang J; Huang JN; Ye Y; Liao M
    Vaccine; 2016 Jan; 34(5):622-629. PubMed ID: 26724200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanovaccine Confers Dual Protection Against Influenza A Virus And Porcine Circovirus Type 2.
    Ding P; Jin Q; Chen X; Yang S; Guo J; Xing G; Deng R; Wang A; Zhang G
    Int J Nanomedicine; 2019; 14():7533-7548. PubMed ID: 31571862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. M2SR, a novel live influenza vaccine, protects mice and ferrets against highly pathogenic avian influenza.
    Hatta Y; Boltz D; Sarawar S; Kawaoka Y; Neumann G; Bilsel P
    Vaccine; 2017 Jul; 35(33):4177-4183. PubMed ID: 28668565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective immunity against influenza virus challenge by norovirus P particle-M2e and HA2-AtCYN vaccines in chickens.
    Elaish M; Xia M; Ngunjiri JM; Ghorbani A; Jang H; Kc M; Abundo MC; Dhakal S; Gourapura R; Jiang X; Lee CW
    Vaccine; 2019 Oct; 37(43):6454-6462. PubMed ID: 31506195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse.
    Mozdzanowska K; Zharikova D; Cudic M; Otvos L; Gerhard W
    Virol J; 2007 Oct; 4():118. PubMed ID: 17974006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-Protective Potential and Protection-Relevant Immune Mechanisms of Whole Inactivated Influenza Virus Vaccines Are Determined by Adjuvants and Route of Immunization.
    Bhide Y; Dong W; Gribonika I; Voshart D; Meijerhof T; de Vries-Idema J; Norley S; Guilfoyle K; Skeldon S; Engelhardt OG; Boon L; Christensen D; Lycke N; Huckriede A
    Front Immunol; 2019; 10():646. PubMed ID: 30984200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with recombinant 4 × M2e.HSP70c fusion protein as a universal vaccine candidate enhances both humoral and cell-mediated immune responses and decreases viral shedding against experimental challenge of H9N2 influenza in chickens.
    Dabaghian M; Latify AM; Tebianian M; Nili H; Ranjbar AR; Mirjalili A; Mohammadi M; Banihashemi R; Ebrahimi SM
    Vet Microbiol; 2014 Nov; 174(1-2):116-26. PubMed ID: 25293397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal adenovirus-vectored vaccine for induction of long-lasting humoral immunity-mediated broad protection against influenza in mice.
    Kim EH; Park HJ; Han GY; Song MK; Pereboev A; Hong JS; Chang J; Byun YH; Seong BL; Nguyen HH
    J Virol; 2014 Sep; 88(17):9693-703. PubMed ID: 24920793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for
    Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R
    mBio; 2017 Sep; 8(5):. PubMed ID: 28928215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine Efficacy of Inactivated, Chimeric Hemagglutinin H9/H5N2 Avian Influenza Virus and Its Suitability for the Marker Vaccine Strategy.
    Kim SM; Kim YI; Park SJ; Kim EH; Kwon HI; Si YJ; Lee IW; Song MS; Choi YK
    J Virol; 2017 Mar; 91(6):. PubMed ID: 28077631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCR2 Regulates Vaccine-Induced Mucosal T-Cell Memory to Influenza A Virus.
    Lee W; Kingstad-Bakke B; Kedl RM; Kawaoka Y; Suresh M
    J Virol; 2021 Jul; 95(15):e0053021. PubMed ID: 33952647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Filling two needs with one deed: a combinatory mucosal vaccine against influenza A virus and respiratory syncytial virus.
    Vieira Antão A; Oltmanns F; Schmidt A; Viherlehto V; Irrgang P; Rameix-Welti MA; Bayer W; Lapuente D; Tenbusch M
    Front Immunol; 2024; 15():1376395. PubMed ID: 38975350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the immunogenicity and protective effects of a trivalent chimeric norovirus P particle immunogen displaying influenza HA2 from subtypes H1, H3 and B.
    Gong X; Yin H; Shi Y; He X; Yu Y; Guan S; Kuai Z; Haji NM; Haji NM; Kong W; Shan Y
    Emerg Microbes Infect; 2016 May; 5(5):e51. PubMed ID: 27222326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung.
    Neuhaus V; Chichester JA; Ebensen T; Schwarz K; Hartman CE; Shoji Y; Guzmán CA; Yusibov V; Sewald K; Braun A
    Vaccine; 2014 May; 32(26):3216-22. PubMed ID: 24731807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal vaccination with influenza HA/GO-PEI nanoparticles provides immune protection against homo- and heterologous strains.
    Dong C; Wang Y; Gonzalez GX; Ma Y; Song Y; Wang S; Kang SM; Compans RW; Wang BZ
    Proc Natl Acad Sci U S A; 2021 May; 118(19):. PubMed ID: 33941704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
    Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
    Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of M2e peptide with stalk HA epitopes of influenza A virus enhances protective properties of recombinant vaccine.
    Tsybalova LM; Stepanova LA; Shuklina MA; Mardanova ES; Kotlyarov RY; Potapchuk MV; Petrov SA; Blokhina EA; Ravin NV
    PLoS One; 2018; 13(8):e0201429. PubMed ID: 30138320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.